Sutura, Inc.
OTC Bulletin Board : SUTU

Sutura, Inc.

January 13, 2006 10:05 ET

Sutura Issues Shareholder Update

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - Jan. 13, 2006) - Sutura, Inc. ("Sutura")(OTCBB:SUTU), a California-based medical device company, today issued an update to its shareholders on the completion its merger with Technology Visions Group. Shareholders of the former privately-held Sutura, Inc. will be sent a Transmittal Letter over the next week instructing them to send their old shares in to the transfer agent to exchange them for new shares in the now publicly trading Company.

Anthony Nobles, President and Chief Executive Officer at Sutura, Inc, stated, "This is essentially a housekeeping matter, as the shareholders of the former private company have been shareholders of the public company since the merger was completed in August. We have been working with our accountants to ensure that each shareholder received the full benefit of the transaction. This work has now been completed, and we are now pleased to instruct our transfer agent to process the transaction."

Shareholders of the formerly privately-held Sutura, Inc. should hold on to their shares until they receive the Transmittal Letter which will direct them to send their shares to Sutura's transfer agent, North American Transfer Co. (147 W. Merrick Road, Freeport, NY 11520-0311, Tel. (516) 379-8501) to be exchanged for shares in the public company (SUTU).

About Sutura, Inc.

Sutura®, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.

Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", "appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed sales and marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information